About AstraZeneca (NYSE:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Industry, Sector and Symbol
Trailing P/E Ratio7.98
Forward P/E Ratio17.95
Sales & Book Value
Annual Sales$23.00 billion
Price / Sales3.70
Cash Flow$3.10 per share
Price / Cash10.82
Book Value$6.59 per share
Price / Book5.09
Net Income$3.50 billion
Return on Equity34.02%
Return on Assets8.37%
AstraZeneca (NYSE:AZN) Frequently Asked Questions
What is AstraZeneca's stock symbol?
AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?
AstraZeneca announced a None dividend on Friday, July 28th. Investors of record on Friday, August 11th will be paid a dividend of $0.44 per share on Monday, September 11th. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. View AstraZeneca's Dividend History.
When did AstraZeneca's stock split? How did AstraZeneca's stock split work?
AstraZeneca shares split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.
How were AstraZeneca's earnings last quarter?
AstraZeneca plc (NYSE:AZN) issued its quarterly earnings results on Thursday, November, 9th. The company reported $1.12 EPS for the quarter, topping the Zacks' consensus estimate of $0.57 by $0.55. The company earned $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.32 EPS. View AstraZeneca's Earnings History.
When will AstraZeneca make its next earnings announcement?
Where is AstraZeneca's stock going? Where will AstraZeneca's stock price be in 2017?
18 Wall Street analysts have issued 1-year price targets for AstraZeneca's shares. Their forecasts range from $34.00 to $39.00. On average, they expect AstraZeneca's stock price to reach $36.60 in the next year. View Analyst Ratings for AstraZeneca.
Who are some of AstraZeneca's key competitors?
Some companies that are related to AstraZeneca include Merck & Co., Inc. (MRK), Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Celgene (CELG), GlaxoSmithKline (GSK), Shire (SHPG), Beximco Pharmaceuticals (BXP), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals International (VRX), Dr.Reddy's Laboratories (RDY), Catalent (CTLT) and Patheon (PTHN).
Who are AstraZeneca's key executives?
AstraZeneca's management team includes the folowing people:
- Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
- Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
- Fiona Cicconi, Executive Vice-President, Human Resources
- Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
- Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
- Ruud Dobber, Executive Vice President, North America
- Bahija Jallal Ph.D., Executive Vice President, MedImmune
- Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
- Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
- Leon Wang, Executive Vice President - Asia Pacific
Who owns AstraZeneca stock?
AstraZeneca's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.46%), Capital International Investors (0.39%), Epoch Investment Partners Inc. (0.29%), Wells Fargo & Company MN (0.17%), Ameriprise Financial Inc. (0.12%) and Capital Bank & Trust Co (0.11%). View Institutional Ownership Trends for AstraZeneca.
Who sold AstraZeneca stock? Who is selling AstraZeneca stock?
AstraZeneca's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, JPMorgan Chase & Co., Todd Asset Management LLC, Epoch Investment Partners Inc., Assetmark Inc., Capital Guardian Trust Co., Sei Investments Co. and Allianz Asset Management GmbH. View Insider Buying and Selling for AstraZeneca.
Who bought AstraZeneca stock? Who is buying AstraZeneca stock?
AstraZeneca's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sector Gamma AS, Janus Henderson Group PLC, Point72 Asset Management L.P., Fisher Asset Management LLC, Dimensional Fund Advisors LP, Great West Life Assurance Co. Can and Wells Fargo & Company MN. View Insider Buying and Selling for AstraZeneca.
How do I buy AstraZeneca stock?
Shares of AstraZeneca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AstraZeneca's stock price today?
One share of AstraZeneca stock can currently be purchased for approximately $33.57.
How big of a company is AstraZeneca?
AstraZeneca has a market capitalization of $84.62 billion and generates $23.00 billion in revenue each year. The company earns $3.50 billion in net income (profit) each year or $2.79 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.
How can I contact AstraZeneca?
AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]
MarketBeat Community Rating for AstraZeneca (AZN)MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
AstraZeneca (NYSE:AZN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Hold||Buy|
|Consensus Rating Score: ||2.54||2.54||2.43||2.62|
|Ratings Breakdown: ||1 Sell Rating(s)|
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
11 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$37.40||$37.40||$34.79||$37.79|
|Price Target Upside: ||12.47% upside||11.26% upside||6.54% upside||9.81% upside|
AstraZeneca (NYSE:AZN) Consensus Price Target History
AstraZeneca (NYSE:AZN) Analyst Ratings History
(Data available from 12/14/2015 forward)
AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart
AstraZeneca (NYSE AZN) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/1/2018|| || || || || || || || |
|11/9/2017||Q3||$0.57||$1.12||$6.00 billion||$6.23 billion||View||N/A|
|7/27/2017||6/30/2017||$0.41||$0.87||$5.04 billion||$5.05 billion||View||N/A|
|4/27/2017||3/31/2017||$0.38||$0.99||$5.40 billion||$5.41 billion||View||N/A|
|2/2/2017||Q416||$0.51||$1.21||$5.43 billion||$5.59 billion||View||Listen|
|11/10/2016||Q316||$0.48||$1.32||$5.95 billion||$5.70 billion||View||N/A|
|7/28/2016||Q216||$0.76||$0.83||$5.56 billion||$5.60 billion||View||Listen|
|4/29/2016||Q1||$0.60||$0.51||$5.96 billion||$6.12 billion||View||Listen|
|2/4/2016||Q415||$0.88||$0.94||$6.27 billion||$6.40 billion||View||N/A|
|11/5/2015||Q315||$0.51||$1.03||$5.90 billion||$5.85 billion||View||N/A|
|7/30/2015||Q2||$0.52||$1.21||$6.02 billion||$5.84 billion||View||Listen|
|4/24/2015||Q1||$1.07||$1.08||$5.87 billion||$6.06 billion||View||N/A|
|2/5/2015||Q314||$0.85||$0.76||$6.68 billion||$6.68 billion||View||N/A|
|11/6/2014||Q3||$1.04||$1.05||$6.44 billion||$6.54 billion||View||N/A|
|7/31/2014||Q214||$1.09||$1.30||$6.24 billion||$6.45 billion||View||N/A|
|4/29/2014||Q114||$1.23||$1.17||$6.32 billion||$6.42 billion||View||N/A|
|2/6/2014||Q413||$1.22||$1.23||$6.91 billion||$3.84 billion||View||N/A|
|10/31/2013||Q313||$1.27||$1.21||$6.45 billion||$6.25 billion||View||N/A|
|8/1/2013||Q213||$1.16||$1.20||$6.24 billion||$6.23 billion||View||N/A|
|4/25/2013||$1.36||$1.41||$6.54 billion||$6.39 billion||View||N/A|
|1/31/2013||Q412||$1.37||$1.56||$7.17 billion||$7.28 billion||View||N/A|
AstraZeneca (NYSE:AZN) Earnings Estimates
2017 EPS Consensus Estimate: $1.94
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
AstraZeneca (NYSE:AZN) Dividend Information
|Most Recent Dividend:||9/11/2017|
|Dividend Growth:||-21.20% (3 Year Average)|
|Payout Ratio:||49.10% (Trailing 12 Months of Earnings) |
73.26% (Based on This Year's Estimates)
76.11% (Based on Next Year's Estimates)
AstraZeneca (NYSE:AZN) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for AstraZeneca (NYSE AZN)
No insider trades for this company have been tracked by MarketBeat.com
AstraZeneca (NYSE AZN) News Headlines
AstraZeneca (NYSE:AZN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement
AstraZeneca (NYSE AZN) Stock Chart for Thursday, December, 14, 2017